Tipranavir: a protease inhibitor for HIV salvage therapy.

about

A review of the toxicity of HIV medications.α-pyrones and their hydroxylated analogs as promising scaffolds against Mycobacterium tuberculosis.

P2860

Q37633495-67672BAE-EA6C-4032-986E-DE92230EBE48 Q47873412-6B4DF07C-59D5-4AE9-A294-8F8249BBAE0F

P2860

Tipranavir: a protease inhibitor for HIV salvage therapy.

Item

http://www.wikidata.org/entity/Q36513619

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Tipranavir: a protease inhibitor for HIV salvage therapy.

@ast

Tipranavir: a protease inhibitor for HIV salvage therapy.

@en

type

Item

label

Tipranavir: a protease inhibitor for HIV salvage therapy.

@ast

Tipranavir: a protease inhibitor for HIV salvage therapy.

@en

prefLabel

Tipranavir: a protease inhibitor for HIV salvage therapy.

@ast

Tipranavir: a protease inhibitor for HIV salvage therapy.

@en

P1476

Tipranavir: a protease inhibitor for HIV salvage therapy.

@en

P2093

Betty J Dong

http://www.w3.org/2001/XMLSchema#string

Jennifer M Cocohoba

http://www.w3.org/2001/XMLSchema#string

P2860

Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir

Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells

In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.

Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.

The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities.

Prevalence of antiretroviral drug resistance in the HIV-1-infected urban indigent population in San Francisco: a representative study.

Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates.

P304

1311-1321

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1G598

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

7-8

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16788094

http://www.w3.org/2001/XMLSchema#string

Tipranavir: a protease inhibitor for HIV salvage therapy.

about

P2860

P2860

Tipranavir: a protease inhibitor for HIV salvage therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698